[ad_1]
The whole world waits for a vaccine against the coronavirus
The American company Moderna announced that its vaccine against the new coronavirus showed an effectiveness of 94.5% in the third stage of trials.
The world is getting closer to the long-awaited coronavirus vaccine. Following the companies Pfizer and BioNTech, the American company Moderna announced its successes in the development of the vaccine. Plus, Moderna’s vaccine promises to be even more effective.
Correspondent.net gathered information on a new vaccine.
Benefits
During the third stage, vaccines were tested on 30,000 people. Two weeks after the second dose of the vaccine, 95 study participants became ill, 90 of whom received a placebo and five received the vaccine, Moderna said in a news release.
Moderna’s vaccine is called mRNA-1273. It is a messenger RNA vaccine: ribonucleic acid acts as a model for the production of viral protein S. It works in a similar way to the Pfizer and BioNTech vaccines.
But Pfizer and BioNTech previously announced that their BNT162b2 coronavirus vaccine was 90% effective in phase III clinical trials. The effectiveness of the Moderna vaccine is 94.5% in the third stage of trials.
If the results continue to be this impressive, the Moderna vaccine could have a huge advantage over the Pfizer vaccine.
While Pfizer’s vaccine requires freezing between -70 ° C and -80 ° C for transport and storage, Moderna said it has improved the shelf life and stability of its own vaccine, and can be stored at standard refrigerated temperatures of 2 ° C to 8 ° C ° C for 30 days. The company also claims that the vaccine can be stored for six months at -20 ° C for transport and long-term storage.
EPA
Modern Company
When to wait
Moderna said she now plans to apply to the US Food and Drug Administration, the state regulator, for permission to use the vaccine in the coming weeks. The Moderna vaccine is not expected to be available outside of the United States until 2021.
The company said it will have 20 million doses ready to ship to the United States by the end of 2020 and expects to produce between 50 million and 1 billion doses worldwide next year.
Peter Openshaw, professor of experimental medicine at Imperial College London, believes Moderna’s results have raised optimism that a selection of good COVID-19 vaccines will be available in the coming months.
Involving at-risk people and the elderly in the vaccine trial Moderna predicts that the vaccine will protect those most vulnerable to the disease, he said.
Made good money
At the same time, the heads of several American laboratories that develop vaccines against Covid-19 have already made millions of dollars by selling shares of their companies.
When the pharmaceutical giant Pfizer announced that preliminary estimates of its coronavirus vaccine were 90% effective, its chief executive, Albert Burla, sold shares worth $ 5.6 million. There was nothing illegal about this, the company said.
“The sale was carried out in accordance with the rules that allow company executives to sell shares with predetermined criteria, on a specific date or at a predetermined price to avoid any suspicion,” said Pfizer.
Under the same rules, several executives at Moderna Pharma have sold more than $ 100 million in shares in recent months. Additionally, the US federal government has pledged to pay Moderna up to $ 2.5 billion if the vaccine proves effective.
Moderna’s stock has risen in price from $ 19 at the beginning of the year to the current level of $ 90.
The Novavax boss, for his part, also sold $ 4.2 million in shares on August 18, just over a month after announcing that the company would receive $ 1.6 billion in government funding.
